Toripalimab with nab-paclitaxel/gemcitabine as first-line treatment for advanced pancreatic adenocarcinoma: Updated results of a single-arm, open-label, phase Ib/II clinical study.

被引：7
|
作者：
Cheng, Ke
Lv, Wan-Rui
Li, Xiaofen
Tian, Bole
Cao, Dan
机构：
[1] Sichuan Univ, West China Hosp, Chengdu, Peoples R China
[2] Sichuan Univ, West China Hosp, Canc Ctr, Dept Abdominal Oncol, Chengdu, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e16213
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16213
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in first-line treatment of claudin 18.2-positive metastatic pancreatic cancer (mPC): Phase 2, open-label, randomized study.
    Park, Wungki
    O'Reilly, Eileen Mary
    Furuse, Junji
    Li, Chung-Pin
    Oh, Do-Youn
    Garcia-Carbonero, Rocio
    Roth, Gael
    Lee, Ho-Jin
    Bhattacharya, Pranob P.
    Moran, Diarmuid Martin
    Yang, Jianning
    Kunieda, Futoshi
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS782 - TPS782
  • [42] Bintrafusp alfa plus paclitaxel for advanced gastric cancer as a second-line treatment: An open label, single-arm, phase Ib/II study.
    Lee, Choong-kun
    Jung, Minkyu
    Park, Sejung
    Kwon, Woo Sun
    Kim, Kyoo Hyun
    Hong, Moonki
    Kim, Hyunwook
    Kim, Hyo Song
    Chung, Hyun Cheol Cheol
    Rha, Sun Young
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 374 - 374
  • [43] Updated efficacy and safety data from a phase II, single-arm, open-label study of durvalumab plus gemcitabine, cisplatin, and nab-paclitaxel (DurGAP) in resectable biliary tract cancer
    Li, Huikai
    Liu, Yang
    Zhang, Xihao
    LANCET REGIONAL HEALTH-WESTERN PACIFIC, 2025, 55
  • [44] Zolbetuximab with gemcitabine plus nab-paclitaxel (GN) in first-line treatment of Claudin 18.2-positive metastatic pancreatic cancer (mPC): Phase II, open-label, randomized study
    Park, W.
    O'Reilly, E. M.
    Li, C-P.
    Oh, D-Y.
    Garcia-Carbonero, R.
    Roth, G.
    Nakajima, T.
    Moran, D.
    Yang, J.
    Li, R.
    Kunieda, F.
    ANNALS OF ONCOLOGY, 2024, 35 : S934 - S934
  • [45] Phase I trial of enzalutamide, gemcitabine, and nab-paclitaxel as a first-line treatment for advanced pancreatic cancer.
    Mahipal, Amit
    Springett, Gregory M.
    Burke, Nancy
    Neuger, Anthony
    Almhanna, Khaldoun
    Wapinsky, Georgine
    Bertels, Barbara
    Kim, Richard D.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [46] Ibrutinib in combination with nab-paclitaxel and gemcitabine as first-line treatment for patients with metastatic pancreatic adenocarcinoma: results from the phase 3 RESOLVE study
    Tempero, M.
    Oh, D.
    Macarulla, T.
    Reni, M.
    Van Cutsem, E.
    Hendifar, A.
    Waldschmidt, D.
    Starling, N.
    Bachet, J.
    Chang, H.
    Maurel, J.
    Lonardi, S.
    Coussens, L.
    Fong, L.
    Tsao, L.
    Cole, G., Jr.
    James, D.
    Tebernero, J.
    ANNALS OF ONCOLOGY, 2019, 30 : 126 - 126
  • [47] Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study
    Tempero, M.
    Oh, D-Y
    Tabernero, J.
    Reni, M.
    Van Cutsem, E.
    Hendifar, A.
    Waldschmidt, D-T
    Starling, N.
    Bachet, J-B
    Chang, H-M
    Maurel, J.
    Garcia-Carbonero, R.
    Lonardi, S.
    Coussens, L. M.
    Fong, L.
    Tsao, L. C.
    Cole, G., Jr.
    James, D.
    Macarulla, T.
    ANNALS OF ONCOLOGY, 2021, 32 (05) : 600 - 608
  • [48] Centchroman as First-line Treatment for Mastalgia: Results of an Open-label, Single-arm Trial
    Rathi, Jalaj
    Chawla, Inderjit
    Singh, Karnail
    Chawla, Arjun
    BREAST JOURNAL, 2016, 22 (04): : 407 - 412
  • [49] Nab-paclitaxel plus capecitabine as first-line treatment for advanced biliary tract cancers: An open-label, non-randomized, phase II clinical trial
    Xu, Ling-Xiao
    Yuan, Jia-Jia
    Xue, Ran
    Zhou, Jun
    WORLD JOURNAL OF GASTROENTEROLOGY, 2024, 30 (30)
  • [50] A multi-center, open-label, randomized controlled trial of nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine for first-line treatment of advanced pancreatic cancer (PC)
    Jin, M.
    Liu, H.
    Lin, Z.
    Xue, J.
    Liu, J.
    Bao, L.
    Luo, Z.
    Yu, X.
    Li, S.
    Hu, J.
    Zhang, T.
    ANNALS OF ONCOLOGY, 2022, 33 : S311 - S311
12345